Invivyd, Inc. (NASDAQ:IVVD) Short Interest Update

Invivyd, Inc. (NASDAQ:IVVD) saw a large drop in short interest in March. As of March 15th, there was short interest totalling 6,660,000 shares, a drop of 28.8% from the February 28th total of 9,360,000 shares. Currently, 8.8% of the company’s stock are sold short. Based on an average daily volume of 14,530,000 shares, the short-interest ratio is presently 0.5 days.

Invivyd Price Performance

Shares of NASDAQ IVVD traded down $0.01 during midday trading on Friday, reaching $0.60. The company’s stock had a trading volume of 1,811,748 shares, compared to its average volume of 4,238,549. The stock has a market capitalization of $71.98 million, a P/E ratio of -0.31 and a beta of 0.09. The firm has a 50 day moving average price of $1.00 and a 200-day moving average price of $0.86. Invivyd has a 12-month low of $0.35 and a 12-month high of $4.74.

Invivyd (NASDAQ:IVVD) last announced its quarterly earnings data on Thursday, March 20th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.10. The business had revenue of $13.80 million during the quarter, compared to the consensus estimate of $13.57 million. On average, equities analysts predict that Invivyd will post -1.64 EPS for the current year.

Insider Buying and Selling

In related news, Director Terrance Mcguire sold 86,545 shares of the company’s stock in a transaction dated Monday, December 30th. The shares were sold at an average price of $0.48, for a total value of $41,541.60. Following the sale, the director now owns 3,170,231 shares in the company, valued at $1,521,710.88. This represents a 2.66 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 17.90% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Mithril II GP LP purchased a new position in Invivyd in the fourth quarter valued at approximately $4,981,000. State Street Corp lifted its position in shares of Invivyd by 3.7% during the 3rd quarter. State Street Corp now owns 1,018,640 shares of the company’s stock valued at $1,039,000 after buying an additional 35,904 shares during the last quarter. Deutsche Bank AG grew its stake in shares of Invivyd by 35.2% during the 4th quarter. Deutsche Bank AG now owns 874,406 shares of the company’s stock worth $385,000 after acquiring an additional 227,463 shares during the period. Two Sigma Investments LP increased its holdings in Invivyd by 125.3% in the 4th quarter. Two Sigma Investments LP now owns 367,100 shares of the company’s stock worth $163,000 after acquiring an additional 204,188 shares during the last quarter. Finally, Two Sigma Advisers LP lifted its holdings in Invivyd by 1,276.5% during the fourth quarter. Two Sigma Advisers LP now owns 304,200 shares of the company’s stock valued at $135,000 after purchasing an additional 282,100 shares during the last quarter. 70.36% of the stock is owned by institutional investors.

Analyst Ratings Changes

IVVD has been the subject of several analyst reports. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Invivyd in a research note on Wednesday. D. Boral Capital reissued a “buy” rating and issued a $9.00 price target on shares of Invivyd in a research report on Thursday, March 20th. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Invivyd has an average rating of “Buy” and an average target price of $7.89.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.